Instruction 1(b).

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>Bjorklund Hakan</u>					2. Issuer Name and Ticker or Trading Symbol Organogenesis Holdings Inc. [ORGO]								Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle) C/O AVISTA HEALTHCARE PUBLIC ACQUISITION					3. Date of Earliest Transaction (Month/Day/Year) 12/10/2018								Officer (give title Other (specify below)				
CORP. 65 EAST 55TH STREET, 18TH FLOOR					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) NEW YORK NY			10022											•	•	ting Person One Reporti	ng
(City)	(S	tate)	(Zip)														
		Ta	ble I - Non	-Deriva	tive S	ecur	ities Ac	quired	, Dis	posed c	of, or Be	eneficially	y Owned				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D						2A. Deemed Execution Date, if any (Month/Day/Yea		, Transaction Dispose Code (Instr. 5)		Dispose	rities Acquired (A) o ed Of (D) (Instr. 3, 4		5. Amoun Securities Beneficia Owned Fo Reported	s Ily ollowing	Form:	Direct II Indirect E str. 4) C	7. Nature of Indirect Beneficial Ownership (Instr. 4)
							Code	v	Amount	(A) (D)	Price	Transacti (Instr. 3 a	ction(s)				
			Table II - [osed of converti			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Cod	saction e (Instr.	Deri Sec Acq or D of (I	umber of ivative urities uired (A) bisposed D) (Instr. and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Cod	e V	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares		(Instr. 4)			
Class B Ordinary Shares	(1)	12/10/2018		D ⁽²⁾			243,896	(1)		(1)	Class A Ordinary Shares	243,896	(2)	69,57	1	D	

Explanation of Responses:

1. Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of Avista Healthcare Public Acquisition Corp. (the "Issuer"), the Class B ordinary shares, par value \$0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value \$0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date.

2. 243,896 Class B ordinary shares were forfeited to the Issuer for no consideration prior to the closing of the Business Combination.

In connection with the closing of the Business Combination, the Issuer's name was changed to Organogenesis Holdings Inc.

/s/ Benjamin Silbert, Attorney-12/12/2018 in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.